|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
| Address1 | One M Street, SE |
Address2 | Suite 510 |
| City | WASHINGTON |
State | DC |
Zip Code | 20003 |
Country | USA |
3. Principal place of business (if different than line 2)
| City |
|
State |
|
Zip Code |
|
Country |
|
|
5. Senate ID# 69674-12
|
||||||||
|
6. House ID# 357890000
|
||||||||
| TYPE OF REPORT | 8. Year | 2026 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
| 10. Check if this is a Termination Report | Termination Date |
|
11. No Lobbying Issue Activity |
| INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| 12. Lobbying | 13. Organizations | ||||||||
| INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
| Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
|
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
|||||||||
| Signature | Digitally Signed By: Bryant Robinson |
Date | 7/20/2026 3:26:42 PM |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code BUD
16. Specific lobbying issues
H.R.8469 - Making appropriations for military construction, the Department of Veterans Affairs, and related agencies for the fiscal year ending September 30, 2027, and for other purposes.
H.R.9260 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2027
H.R.9495 - Department of Defense Appropriations Act, 2027
Advocated for funding levels in FY27 appropriations bills: $51.303 billion for the National Institutes of Health (NIH) for fiscal year (FY) 2027. In April joined with coalition partners on a Congressional letter requesting $90.47 Million for the NIEHS Superfund Program, including the SRP and WTP.These programs are housed in NIH. Supporting established funding levels for Medicare and Medicaid and protection of Medicaid's current financing structure.
DoD- Working to ensure $1.626 billion in funding for the Congressionally Directed MS Research Program in FY 27. Specifically advocating for $22 million for the MS Research Program.
In May, joined with coalition partners to thank SAC and HAC LHHS committees for including provisions aimed at safeguarding public health investments. Additionally joined with coalition partners on a letter to Defense committee leadership to increase funding for the Congressionally Directed Medical Research Programs (CDMRP) at the Department of Defense (DoD).
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Centers For Medicare and Medicaid Services (CMS), Defense - Dept of (DOD), Veterans Affairs - Dept of (VA), Natl Institutes of Health (NIH)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Nicole |
Boschi |
|
|
|
Bryant |
Robinson |
|
|
|
Steffany |
Stern |
|
|
|
Ashleigh |
Tharp |
|
|
|
Suzanne |
Gragg |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
H.R. 1 - One Big Beautiful Bill Act (implementation)
H.R. 1509 - Accelerating Kids' Access to Care Act of 2025
H.R. 2036 - Credit for Caring Act of 2025
H.R. 2079 - Insurance Fraud Accountability Act
H.R. 2320 - Mobility Means Freedom Tax Credit Act
H.R. 2560 - Lifespan Respite Care Reauthorization Act of 2025
H.R. 3417 - Websites and Software Applications Accessibility Act of 2025
H.R. 3514 - Improving Seniors' Timely Access to Care Act of 2025
H.R. 3907 - ENROLL Act of 2025
H.R.4317 - PBM Reform Act of 2025
H.R.5081 - Telehealth Modernization Act
H.R. 5940, the Seniors Deserve Streamlined Medical Approvals for Timely, Efficient, Recovery (SMARTER) Care Act of 2025
H.R.6183 - To amend the Internal Revenue Code of 1986 to reform certain rules related to health savings accounts.
H.R.6837 - To amend the Employee Retirement Income Security Act of 1974 to ensure that pharmacy benefit managers are considered fiduciaries, and for other purposes.
H.R. 8270: Every Dollar Counts Act of 2026
S. 752 - Accelerating Kids' Access to Care Act
S. 830 - Lifespan Respite Care Reauthorization Act of 2025
S. 925 - Credit for Caring Act of 2025
S. 976 - Insurance Fraud Accountability Act
S. 1816 - Improving Seniors' Timely Access to Care Act of 2025
S. 2024 - ENROLL Act of 2025
S. 3549 - PBM FAIR Act
S. 3386 - Health Care Freedom for Patients Act of 2025
Submitted comments to Department of Labor on its proposed rule: Improving Transparency Into Pharmacy Benefit Manager Fee Disclosure.
Submitted comments to the Food and Drug Administration (FDA) on the Impacts of Patient-Focused Drug Development Meetings. The comments emphasized the meetings are of critical importance for capturing meaningful, disease-specific patient input at scale.
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Food & Drug Administration (FDA), Health & Human Services - Dept of (HHS), Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Labor - Dept of (DOL)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Nicole |
Boschi |
|
|
|
Bryant |
Robinson |
|
|
|
Steffany |
Stern |
|
|
|
Suzanne |
Gragg |
|
|
|
Ashleigh |
Tharp |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MMM
16. Specific lobbying issues
H.R.1 - One Big Beautiful Bill Act
Continued to advocate on H.R.1 implementation.
Submitted and joined coalition comments to CMS on the proposed rule on Interoperability Standards and Prior Authorization for Drugs. The aimed looked to modernize prior authorization processes and improve interoperability across the healthcare system.
Joined with coalition partners to respond to a pair of proposed Local Coverage Determinations (LCDs) and the impacts how it would impact how power seat elevation systems are covered under Medicare.
In May, Joined a coalition letter to Congress requesting outreach to CMS to encourage the agency to rescind the Low Vision Aid Exclusion under the Medicare regulations.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Centers For Medicare and Medicaid Services (CMS), Office of Administration
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Nicole |
Boschi |
|
|
|
Steffany |
Stern |
|
|
|
Bryant |
Robinson |
|
|
|
Suzanne |
Gragg |
|
|
|
Ashleigh |
Tharp |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MED
16. Specific lobbying issues
H.R.1 - One Big Beautiful Bill Act
H.R.7779 - Healthy Brains Act of 2026
H.R.9260 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2027
Over the course of the last quarter joined with various coalition partners to advocate for NIH funding grants for medical research.
Submitted comments to the National Institutes of Health on the agency's request for feedback on its Framework for the next NIH-Wide Strategic Plan.
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), Defense - Dept of (DOD), Food & Drug Administration (FDA), Veterans Affairs - Dept of (VA), U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Nicole |
Boschi |
|
|
|
Bryant |
Robinson |
|
|
|
Suzanne |
Gragg |
|
|
|
Ashleigh |
Tharp |
|
|
|
Steffany |
Stern |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TRA
16. Specific lobbying issues
H.R. 9373: Air Carrier Access Amendments Act of 2026
S. 4829: Air Carrier Access Amendments Act
In April joined with coalition partners a letter to the Department Of Transportation requesting updates on the status of DOTs implementation of the disability-related provisions of the FAA Reauthorization Act of 2024 and urging DOT to meet the requirements specified by Congress.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Transportation - Dept of (DOT)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Nicole |
Boschi |
|
|
|
Bryant |
Robinson |
|
|
|
Steffany |
Stern |
|
|
|
Ashleigh |
Tharp |
|
|
|
Suzanne |
Gragg |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
| Address |
|
||||||
| City |
|
State |
|
Zip Code |
|
Country |
|
21. Client new principal place of business (if different than line 20)
| City |
|
State |
|
Zip Code |
|
Country |
|
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
| 1 |
|
3 |
|
||||||
| 2 |
|
4 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
| Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
||||||||||||||
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
| 1 | 2 | 3 |
FOREIGN ENTITIES
27. Add the following foreign entities:
| Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% | |||||||||||||
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
| 1 | 3 | 5 |
| 2 | 4 | 6 |
CONVICTIONS DISCLOSURE
29. Have any of the lobbyists listed on this report been convicted in a Federal or State Court of an offense involving bribery,
extortion, embezzlement, an illegal kickback, tax evasion, fraud, a conflict of interest, making a false statement, perjury, or money laundering?
| Lobbyist Name | Description of Offense(s) |